Skip to main content

Data may help cancer drug gain approval for wider use

 |  By HealthLeaders Media Staff  
   December 11, 2007

Clinical-trial results showing that the blood-cancer drug Velcade increases remission rates in patients could boost its chances of winning regulatory approval for wider use. Velcade currently is approved in the United States to treat multiple myeloma in patients who have received at least one prior therapy.

Full story

Tagged Under:

Get the latest on healthcare leadership in your inbox.